Health
AHA: A Novel Monoclonal Antibody Therapy Cuts LDL Cholesterol by Half in a High-Risk Patient Population, Study Shows – Cath Lab Digest
November 16, 2020 — The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients…
November 16, 2020 The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterolthe so-called bad cholesterolby 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, were presented as late breaking science at the American Heart Association Scientific Sessions 2020 on…
-
General11 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General14 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News13 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business11 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher